Cargando…

Prognostic ability of the German version of the STarT Back tool: analysis of 12-month follow-up data from a randomized controlled trial

BACKGROUND: Stratified care is an up-to-date treatment approach suggested for patients with back pain in several guidelines. A comprehensively studied stratification instrument is the STarT Back Tool (SBT). It was developed to stratify patients with back pain into three subgroups, according to their...

Descripción completa

Detalles Bibliográficos
Autores principales: Karstens, Sven, Krug, Katja, Raspe, Heiner, Wunderlich, Max, Hochheim, Martin, Joos, Stefanie, Hüppe, Angelika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393968/
https://www.ncbi.nlm.nih.gov/pubmed/30819162
http://dx.doi.org/10.1186/s12891-019-2467-6
_version_ 1783398794783621120
author Karstens, Sven
Krug, Katja
Raspe, Heiner
Wunderlich, Max
Hochheim, Martin
Joos, Stefanie
Hüppe, Angelika
author_facet Karstens, Sven
Krug, Katja
Raspe, Heiner
Wunderlich, Max
Hochheim, Martin
Joos, Stefanie
Hüppe, Angelika
author_sort Karstens, Sven
collection PubMed
description BACKGROUND: Stratified care is an up-to-date treatment approach suggested for patients with back pain in several guidelines. A comprehensively studied stratification instrument is the STarT Back Tool (SBT). It was developed to stratify patients with back pain into three subgroups, according to their risk of persistent disabling symptoms. The primary aim was to analyse the disability differences in patients with back pain 12 months after inclusion according to the subgroups determined at baseline using the German version of the SBT (STarT-G). Moreover, the potential to improve prognosis for disability by adding further predictor variables, an analysis for differences in pain intensity according to the STarT-Classification, and discriminative ability were investigated. METHODS: Data from the control group of a randomized controlled trial were analysed. Trial participants were members of a private medical insurance with a minimum age of 18 and indicated as having persistent back pain. Measurements were made for the risk of back pain chronification using the STarT-G, disability (as primary outcome) and back pain intensity with the Chronic Pain Grade Scale (CPGS), health-related quality of life with the SF-12, psychological distress with the Patient Health Questionnaire-4 (PHQ-4) and physical activity. Analysis of variance (ANOVA), multiple linear regression, and area under the curve (AUC) analysis were conducted. RESULTS: The mean age of the 294 participants was 53.5 (SD 8.7) years, and 38% were female. The ANOVA for disability and pain showed significant differences (p < 0.01) among the risk groups at 12 months. Post hoc Tukey tests revealed significant differences among all three risk groups for every comparison for both outcomes. AUC for STarT-G’s ability to discriminate reference standard ‘cases’ for chronic pain status at 12 months was 0.79. A prognostic model including the STarT-Classification, the variables global health, and disability at baseline explained 45% of the variance in disability at 12 months. CONCLUSIONS: Disability differences in patients with back pain after a period of 12 months are in accordance with the subgroups determined using the STarT-G at baseline. Results should be confirmed in a study developed with the primary aim to investigate those differences.
format Online
Article
Text
id pubmed-6393968
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63939682019-03-11 Prognostic ability of the German version of the STarT Back tool: analysis of 12-month follow-up data from a randomized controlled trial Karstens, Sven Krug, Katja Raspe, Heiner Wunderlich, Max Hochheim, Martin Joos, Stefanie Hüppe, Angelika BMC Musculoskelet Disord Research Article BACKGROUND: Stratified care is an up-to-date treatment approach suggested for patients with back pain in several guidelines. A comprehensively studied stratification instrument is the STarT Back Tool (SBT). It was developed to stratify patients with back pain into three subgroups, according to their risk of persistent disabling symptoms. The primary aim was to analyse the disability differences in patients with back pain 12 months after inclusion according to the subgroups determined at baseline using the German version of the SBT (STarT-G). Moreover, the potential to improve prognosis for disability by adding further predictor variables, an analysis for differences in pain intensity according to the STarT-Classification, and discriminative ability were investigated. METHODS: Data from the control group of a randomized controlled trial were analysed. Trial participants were members of a private medical insurance with a minimum age of 18 and indicated as having persistent back pain. Measurements were made for the risk of back pain chronification using the STarT-G, disability (as primary outcome) and back pain intensity with the Chronic Pain Grade Scale (CPGS), health-related quality of life with the SF-12, psychological distress with the Patient Health Questionnaire-4 (PHQ-4) and physical activity. Analysis of variance (ANOVA), multiple linear regression, and area under the curve (AUC) analysis were conducted. RESULTS: The mean age of the 294 participants was 53.5 (SD 8.7) years, and 38% were female. The ANOVA for disability and pain showed significant differences (p < 0.01) among the risk groups at 12 months. Post hoc Tukey tests revealed significant differences among all three risk groups for every comparison for both outcomes. AUC for STarT-G’s ability to discriminate reference standard ‘cases’ for chronic pain status at 12 months was 0.79. A prognostic model including the STarT-Classification, the variables global health, and disability at baseline explained 45% of the variance in disability at 12 months. CONCLUSIONS: Disability differences in patients with back pain after a period of 12 months are in accordance with the subgroups determined using the STarT-G at baseline. Results should be confirmed in a study developed with the primary aim to investigate those differences. BioMed Central 2019-02-28 /pmc/articles/PMC6393968/ /pubmed/30819162 http://dx.doi.org/10.1186/s12891-019-2467-6 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Karstens, Sven
Krug, Katja
Raspe, Heiner
Wunderlich, Max
Hochheim, Martin
Joos, Stefanie
Hüppe, Angelika
Prognostic ability of the German version of the STarT Back tool: analysis of 12-month follow-up data from a randomized controlled trial
title Prognostic ability of the German version of the STarT Back tool: analysis of 12-month follow-up data from a randomized controlled trial
title_full Prognostic ability of the German version of the STarT Back tool: analysis of 12-month follow-up data from a randomized controlled trial
title_fullStr Prognostic ability of the German version of the STarT Back tool: analysis of 12-month follow-up data from a randomized controlled trial
title_full_unstemmed Prognostic ability of the German version of the STarT Back tool: analysis of 12-month follow-up data from a randomized controlled trial
title_short Prognostic ability of the German version of the STarT Back tool: analysis of 12-month follow-up data from a randomized controlled trial
title_sort prognostic ability of the german version of the start back tool: analysis of 12-month follow-up data from a randomized controlled trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393968/
https://www.ncbi.nlm.nih.gov/pubmed/30819162
http://dx.doi.org/10.1186/s12891-019-2467-6
work_keys_str_mv AT karstenssven prognosticabilityofthegermanversionofthestartbacktoolanalysisof12monthfollowupdatafromarandomizedcontrolledtrial
AT krugkatja prognosticabilityofthegermanversionofthestartbacktoolanalysisof12monthfollowupdatafromarandomizedcontrolledtrial
AT raspeheiner prognosticabilityofthegermanversionofthestartbacktoolanalysisof12monthfollowupdatafromarandomizedcontrolledtrial
AT wunderlichmax prognosticabilityofthegermanversionofthestartbacktoolanalysisof12monthfollowupdatafromarandomizedcontrolledtrial
AT hochheimmartin prognosticabilityofthegermanversionofthestartbacktoolanalysisof12monthfollowupdatafromarandomizedcontrolledtrial
AT joosstefanie prognosticabilityofthegermanversionofthestartbacktoolanalysisof12monthfollowupdatafromarandomizedcontrolledtrial
AT huppeangelika prognosticabilityofthegermanversionofthestartbacktoolanalysisof12monthfollowupdatafromarandomizedcontrolledtrial